Beijing Luzhu Biotechnology 将来の成長
Future 基準チェック /26
Beijing Luzhu Biotechnology is forecast to grow earnings and revenue by 47.5% and 59.7% per annum respectively. EPS is expected to grow by 19.3% per annum. Return on equity is forecast to be -403% in 3 years.
主要情報
47.5%
収益成長率
19.3%
EPS成長率
| Biotechs 収益成長 | 41.8% |
| 収益成長率 | 59.7% |
| 将来の株主資本利益率 | -403.0% |
| アナリストカバレッジ | Low |
| 最終更新日 | 24 Sep 2024 |
今後の成長に関する最新情報
Recent updates
業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2026 | 528 | -126 | -156 | -106 | 3 |
| 12/31/2025 | 67 | -349 | -331 | -268 | 3 |
| 12/31/2024 | 1 | -278 | -276 | -205 | 3 |
| 6/30/2024 | N/A | -280 | -235 | -167 | N/A |
| 3/31/2024 | N/A | -265 | -255 | -179 | N/A |
| 12/31/2023 | N/A | -249 | -276 | -190 | N/A |
| 9/30/2023 | N/A | -201 | -307 | -153 | N/A |
| 6/30/2023 | N/A | -152 | -339 | -117 | N/A |
| 3/31/2023 | N/A | -439 | -314 | -97 | N/A |
| 12/31/2022 | N/A | -725 | -289 | -77 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: 2480 is forecast to remain unprofitable over the next 3 years.
収益対市場: 2480 is forecast to remain unprofitable over the next 3 years.
高成長収益: 2480 is forecast to remain unprofitable over the next 3 years.
収益対市場: 2480's revenue (59.7% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
高い収益成長: 2480's revenue (59.7% per year) is forecast to grow faster than 20% per year.
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: 2480 is forecast to be unprofitable in 3 years.